Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
Open Access
- 3 November 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (3) , e534-e540
Abstract
Background: Some individuals with human immunodeficiency virus (HIV-1) have acquired multidrug-resistant (MDR) strains of HIV and/or are nonadherent to antiretroviral (ARV) medication. Injectable ARVs can provide salvage therapy for those with limited therapeutic options and may be preferred by some people with HIV (PWH). Real-world evidence may contribute to a more comprehensive understanding of the barriers to adherence and the utility of injectable ARVs in PWH. Currently, there is a lack of data on combined use of injectable ibalizumab (IBA) and lenacapavir (LEN) with optimized background regimen (OBR). Methods: A retrospective observational study examined medical charts from people with MDR HIV across 8 facilities in the United States. All PWH used a combination of both IBA + LEN ± OBR for at least 6 months. Viral loads and CD4+ counts were collected. Results: A total of 21 PWH were included. Four-class resistance at baseline was reported in 38.1% of PWH. Within 12 to 24 weeks of combined IBA + LEN treatment, a median reduction of −2710 copies/mL HIV RNA was observed. Median increase to CD4+ count was 67.5 cells/mm3 within 4 to 44 weeks of treatment initiation. Few intolerances required changes to treatment. Therapy with IBA + LEN continued for an average of 30 months and 20 months, respectively. Conclusions: In this small group of individuals with MDR HIV who were heavily treatment-experienced and/or faced adherence challenges, the use of IBA + LEN ± OBR was well tolerated and led to clinically significant reductions in viral loads and improvements in CD4+ counts.Keywords
Funding Information
- Theratechnologies Inc
This publication has 19 references indexed in Scilit:
- High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherenceJournal of Medical Virology, 2024
- Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summaryPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a TrialOpen Forum Infectious Diseases, 2024
- Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1Infectious Diseases and Therapy, 2023
- Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureClinical Infectious Diseases, 2023
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionNew England Journal of Medicine, 2022
- Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014–2018Clinical Infectious Diseases, 2021
- Social Determinants of Health and Care Outcomes Among People With HIV in the United StatesOpen Forum Infectious Diseases, 2021
- HIV MDR is still a relevant issue despite its dramatic drop over the yearsJournal of Antimicrobial Chemotherapy, 2020
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1New England Journal of Medicine, 2018